Non Statin LDL
High LDL blood levels is a common problem that has an association with cardiovascular disease. Numerous therapies are currently marketed and it has been suggested 30% of the US population could benefit from LDL lowering products.
The current standard of care are Statin type products. Statins lower LDL cholesterol and total cholesterol levels. At the same time, they lower triglycerides and raise HDL cholesterol levels. Statins may also help to stabilize plaques in the arteries. A fair number of side effects are related to this treatment.
Our product is a Triazolepyrmidizole that has been demonstrated to lower circulating ApoB/LDL levels by 30-40% in animal studies using humanized liver. The product targets direct reduction at the intracellular level. This is especially important to Statin resistant LDL treatments.
- Tissue culture and Murine studies confirm reduction in ApoB/LDL
- Treatment of mice with humanized livers confirms ApoB reduction (ApoA1 not affected)
- PK and TK information available
- Patent issued (composition of matter)
Humanized mouse liver control vs our product % reduction